Pharmaceutics: Dosage Forms & Bioavailability

1. Learning Objectives

Upon successful completion of this module, students will be able to:

• Define and classify various pharmaceutical dosage forms.
• Explain the rationale behind the design and selection of specific dosage forms.
• Describe the fundamental principles governing the formulation of solid, liquid, semi-solid, and specialized dosage forms.
• Define bioavailability, its significance, and the factors that influence it.
• Distinguish between absolute and relative bioavailability, and understand methods for their determination.
• Understand the concept of bioequivalence and its critical role in generic drug substitution.
• Identify and explain strategies employed to enhance drug bioavailability.
• Recognize the clinical implications of dosage form design and bioavailability on therapeutic outcomes.
• Evaluate the safety considerations associated with dosage forms and bioavailability issues.
• Apply knowledge of pharmaceutics to competitive examination questions (e.g., GPAT, NIPER).

2. Introduction to Pharmaceutics, Dosage Forms, and Bioavailability

Pharmaceutics is the discipline within pharmaceutical sciences concerned with the process of turning a new chemical entity (NCE) or old drugs into a medication that can be safely and effectively used by patients. It encompasses the design, formulation, manufacture, and evaluation of pharmaceutical products, commonly known as dosage forms. The primary goal is to ensure the drug reaches its site of action in the body in sufficient concentration and at the correct rate to elicit a therapeutic response, while minimizing adverse effects. This intricate journey of a drug from its administration to systemic circulation, and ultimately to its target, is profoundly influenced by its dosage form and a critical pharmacokinetic parameter known as bioavailability.

A dosage form is the physical form in which a drug is produced and dispensed, such as a tablet, capsule, or injectable solution. It is the vehicle for drug delivery, designed to optimize drug stability, patient compliance, and most importantly, drug release and absorption. Bioavailability, on the other hand, quantifies the fraction of an administered dose of unchanged drug that reaches the systemic circulation and is available to produce a pharmacological effect. Understanding the interplay between dosage form design and bioavailability is paramount for rational drug development, clinical practice, and regulatory approval.

3. Basic Principles of Dosage Form Design

The design of a pharmaceutical dosage form is a complex process influenced by several factors, including the physicochemical properties of the drug, the desired route of administration, the target patient population, and the desired therapeutic effect. The overarching principles ensure drug efficacy, safety, stability, and patient acceptability.

3.1. Physicochemical Properties of the Drug Substance

• Solubility: A drug must possess adequate solubility in biological fluids to be absorbed. Poorly soluble drugs often require specialized formulation strategies.
• Partition Coefficient (Log P): Represents the lipophilicity/hydrophilicity balance, influencing permeability across biological membranes.
• pH and pKa: Affects the ionization state of the drug, which in turn impacts solubility and permeability.
• Particle Size: Crucial for dissolution rate, especially for poorly soluble drugs, and for uniform content in solid dosage forms.
• Polymorphism: Different crystalline forms can exhibit varying solubility, dissolution rates, and stability, impacting bioavailability.
• Stability: The drug must be stable under various environmental conditions (light, temperature, humidity, pH) during manufacturing, storage, and administration.

3.2. Biopharmaceutical Considerations

• Route of Administration: Determines the type of dosage form (e.g., oral, parenteral, topical, inhaled).
• Mechanism of Absorption: Passive diffusion, active transport, facilitated diffusion, endocytosis.
• First-Pass Metabolism: Extent of drug metabolism before reaching systemic circulation, particularly significant for orally administered drugs.
• Desired Onset and Duration of Action: Influences immediate-release vs. sustained-release formulations.
• Target Site: Local vs. systemic effect.

3.3. Patient Considerations

• Age: Pediatric and geriatric patients may require different dosage forms (e.g., liquids for children, easy-to-swallow tablets for the elderly).
• Compliance: Ease of administration, frequency of dosing, taste, and aesthetics.
• Disease State: Impaired liver or kidney function, dysphagia.

4. Classification of Dosage Forms

Dosage forms are broadly classified based on their physical state, route of administration, and mode of release.

4.1. Solid Dosage Forms

Solid dosage forms are the most common and preferred type due to their stability, accuracy of dosing, and patient convenience.

4.1.1. Tablets

• Advantages: Accuracy of dose, compactness, portability, chemical and physical stability, low cost, ease of administration, elegant appearance.
• Disadvantages: Difficulty in swallowing for some patients, potential for poor bioavailability for poorly soluble/absorbable drugs, taste masking challenges.
• Types of Tablets:
  • Uncoated Tablets: Single layer, compressed powder.
  • Coated Tablets:
    • Sugar-coated: Protects drug, masks taste, enhances appearance.
    • Film-coated: Thin polymer layer, more durable, less bulky than sugar coats.
    • Enteric-coated: Resist dissolution in acidic stomach pH, dissolve in alkaline intestinal pH, protecting acid-labile drugs or preventing gastric irritation.
  • Chewable Tablets: Designed to be chewed, useful for pediatric/geriatric patients.
  • Effervescent Tablets: Contain bicarbonate and an organic acid, produce CO2 upon contact with water, masking taste and enhancing absorption (e.g., aspirin).
  • Buccal and Sublingual Tablets: Dissolve in the buccal pouch or under the tongue for rapid systemic absorption, bypassing first-pass metabolism.
  • Sustained-Release (SR) / Extended-Release (ER) Tablets: Formulated to release the drug over an extended period, reducing dosing frequency.
• Excipients in Tablets:
  • Diluents/Fillers: Add bulk (e.g., lactose, microcrystalline cellulose).
  • Binders: Promote particle adhesion (e.g., povidone, starch paste).
  • Disintegrants: Facilitate tablet breakup (e.g., croscarmellose sodium, sodium starch glycolate).
  • Lubricants: Reduce friction during compression (e.g., magnesium stearate).
  • Glidants: Improve powder flow (e.g., colloidal silicon dioxide).
  • Colorants/Flavorants: Improve aesthetics and patient acceptability.

4.1.2. Capsules

• Advantages: Taste masking, ease of swallowing, flexible formulation, rapid drug release (especially hard gelatin capsules), protection of unstable drugs.
• Disadvantages: Prone to moisture, potential for tampering, limited use for highly soluble salts (may cause irritation if concentrated).
• Types of Capsules:
  • Hard Gelatin Capsules: Consist of two pre-fabricated cylindrical halves (body and cap) that are filled with powdered or granulated drug. Often contain diluents, lubricants, and glidants.
  • Soft Gelatin Capsules (Softgels): Single, hermetically sealed unit containing liquid, semi-solid, or suspension. Shell is thicker and more flexible, good for oils and highly potent drugs.
• Filling Materials: Powders, granules, pellets, semi-solids, liquids (non-aqueous).

4.1.3. Powders and Granules

• Powders: Intimate mixtures of dry, finely divided drug and/or excipients. Can be bulk (e.g., antacids) or divided (e.g., antibiotic sachets).
• Granules: Aggregates of powder particles, typically 2-4 mm in size. Better flow properties and compressibility than fine powders, less prone to segregation. Used for effervescent preparations or as intermediates for tablet/capsule manufacturing.

4.1.4. Suppositories and Pessaries

• Suppositories: Solid dosage forms for rectal administration, designed to melt or dissolve at body temperature, releasing the drug for local or systemic effect. Bases include cocoa butter, glycerinated gelatin, PEG.
• Pessaries: Vaginal suppositories, typically larger than rectal suppositories, for local action (e.g., antifungal, contraceptive).

4.2. Liquid Dosage Forms

Liquid dosage forms are homogeneous or heterogeneous preparations intended for oral, topical, or parenteral administration.

• Advantages: Easier to swallow (pediatric/geriatric), faster drug absorption than solids, uniform distribution of drug, flexibility in dosing.
• Disadvantages: Less stable than solids, accurate dosing requires patient compliance, bulkier, potential for taste issues, microbial contamination.

4.2.1. Solutions

• Components: Drug, solvent, cosolvents, solubilizers, preservatives, antioxidants, buffers, flavorants, colorants.
• Types: Syrups (sugar-based), Elixirs (hydroalcoholic), Tinctures (alcoholic extracts), Sprays, Drops.

4.2.2. Suspensions

• Key Considerations: Physical stability (preventing caking/settling), uniform dispersion upon shaking.
• Flocculated vs. Deflocculated:
  • Flocculated: Particles form loose aggregates, settle rapidly but easily redispersed.
  • Deflocculated: Particles settle slowly but form a compact cake, difficult to redisperse.
• Stabilizers: Suspending agents (e.g., cellulose derivatives, gums), wetting agents (e.g., polysorbates).

4.2.3. Emulsions

• Types: Oil-in-Water (O/W) and Water-in-Oil (W/O). O/W are generally preferred for oral use.
• Emulsifying Agents: Reduce interfacial tension, form a protective film around droplets (e.g., acacia, tragacanth, Tween, Span).
• Instabilities: Creaming, sedimentation, flocculation, coalescence, cracking.

4.3. Semi-Solid Dosage Forms

Semi-solid dosage forms are intended for topical application to the skin or mucous membranes.

• Advantages: Localized drug delivery, avoids first-pass metabolism, high drug concentration at the site of action, patient self-administration.
• Disadvantages: Messy, greasy, patient compliance issues, limited systemic absorption (unless designed for transdermal).

4.3.1. Ointments

• Bases: Oleaginous (petrolatum), Absorption (lanolin), Water-removable (hydrophilic ointment), Water-soluble (PEG bases).
• Occlusivity: Ointments are generally more occlusive, promoting hydration and drug penetration.

4.3.2. Creams

• Types: Vanishing creams (O/W), Cold creams (W/O).
• Feel: Less greasy, more cosmetically acceptable.

4.3.3. Gels

• Characteristics: Clear, non-greasy, good for areas with hair.
• Thixotropy: Many gels become fluid upon shaking and then revert to a semi-solid state.

4.3.4. Pastes

Contain a higher proportion of solid material (e.g., zinc oxide paste) than ointments, making them stiffer and more protective/absorbent. Often used for weeping lesions.

4.4. Sterile Dosage Forms

Sterile dosage forms are free from viable microorganisms and pyrogens. They are critical for parenteral, ophthalmic, and certain otic and nasal preparations.

4.4.1. Parenterals (Injections)

• Advantages: Rapid onset of action, precise dose, avoids first-pass metabolism, suitable for uncooperative patients or drugs inactivated orally.
• Disadvantages: Requires sterile technique, pain at injection site, potential for infection, higher cost, skilled personnel needed.
• Routes:
  • Intravenous (IV): Directly into a vein, 100% bioavailability, rapid effect.
  • Intramuscular (IM): Into muscle, slower absorption than IV.
  • Subcutaneous (SC): Under the skin, slower absorption, smaller volumes.
  • Intradermal (ID): Into the dermis, for diagnostic tests or vaccines.
• Key Requirements: Sterility, freedom from pyrogens, clarity, isotonicity (for IV), appropriate pH.

4.4.2. Ophthalmic Preparations

Sterile solutions, suspensions, or ointments applied to the eye. Must be isotonic and non-irritating (e.g., eye drops, eye ointments).

4.5. Specialized Dosage Forms

4.5.1. Transdermal Patches

Provide controlled drug delivery across the skin into systemic circulation, bypassing first-pass metabolism. Consist of a backing, drug reservoir, adhesive, and protective liner (e.g., nitroglycerin, nicotine, fentanyl).

4.5.2. Inhalation Products

Deliver drugs to the lungs for local or systemic effects (e.g., MDIs, DPIs, nebulizers). Crucial for respiratory diseases like asthma and COPD.

5. Bioavailability

It is a fundamental pharmacokinetic parameter representing the rate and extent to which the active drug ingredient is absorbed from a drug product and becomes available at the site of action.

5.1. Significance of Bioavailability

• Therapeutic Efficacy: Directly impacts the amount of drug available to exert its effect. Low bioavailability can lead to sub-therapeutic levels.
• Dose Determination: Essential for calculating the correct dose for a given route of administration. For instance, an oral dose is often higher than an IV dose due to incomplete absorption and first-pass metabolism.
• Drug Product Selection: Guides the choice of appropriate dosage form.
• Generic Drug Substitution: Ensures that generic drugs are therapeutically equivalent to brand-name drugs through bioequivalence studies.
• Inter-patient Variability: Explains why some patients respond differently to the same dose of a drug.

5.2. Factors Affecting Bioavailability

Bioavailability is a complex interplay of drug properties, physiological factors, and formulation characteristics.

5.2.1. Drug-Related Factors

• A. Aqueous Solubility: Drugs must be in solution to be absorbed. Poorly soluble drugs (e.g., griseofulvin, phenytoin) have limited bioavailability.
• B. Dissolution Rate: For solid dosage forms, the rate at which the drug dissolves from the solid into gastrointestinal fluids is often the rate-limiting step for absorption. Factors affecting dissolution:
  • Particle Size: Smaller particles (e.g., micronization, nanocrystallization) increase surface area, enhancing dissolution.
  • Polymorphism/Amorphous State: Amorphous forms generally have higher solubility and dissolution rates than crystalline forms. Different crystalline polymorphs can also vary.
  • Salt Form: Salt forms of weak acids or bases often have higher solubility than their unionized counterparts.
  • Crystal Habit: Shape of crystals.
• C. Membrane Permeability: The ability of the drug to cross biological membranes, primarily dependent on lipophilicity (Log P), molecular size, and ionization state (pKa and environmental pH). Unionized, lipophilic drugs generally cross membranes more readily.
• D. Chemical Stability: Degradation of the drug in the GI tract (e.g., acid hydrolysis of penicillin G) reduces the amount available for absorption.

5.2.2. Patient-Related (Physiological) Factors

• A. Gastric Emptying Rate: The rate at which stomach contents move into the small intestine. Rapid emptying often increases absorption, especially for drugs absorbed in the intestine. Food, exercise, and certain drugs can influence it.
• B. Gastrointestinal pH: Affects drug ionization and stability. Drugs that are weak acids are better absorbed in the stomach (low pH), while weak bases are better absorbed in the intestine (higher pH).
• C. Intestinal Motility: Affects residence time at absorption sites. Very rapid transit may reduce absorption time.
• D. Presence of Food: Can either increase (e.g., fat-soluble vitamins, griseofulvin) or decrease (e.g., tetracyclines with dairy) absorption. Food can delay gastric emptying.
• E. Disease States: Malabsorption syndromes (e.g., Crohn's disease), liver disease (impaired metabolism), kidney disease (altered excretion), cardiac failure (reduced blood flow to GI tract).
• F. Blood Flow to the GI Tract: Reduced blood flow can decrease absorption.

5.2.3. Formulation-Related Factors (Excipients and Dosage Form)

• A. Excipients:
  • Disintegrants: Ensure rapid breakdown of solid dosage forms.
  • Binders: Can sometimes reduce dissolution if excessively used.
  • Surfactants: Can improve wetting and dissolution of hydrophobic drugs.
  • Complexing Agents: Can form soluble complexes (e.g., cyclodextrins) or insoluble ones, affecting absorption.
  • Lubricants: Hydrophobic lubricants (e.g., magnesium stearate) can sometimes retard dissolution if present in high concentrations.
• B. Dosage Form Type: Solutions > Suspensions > Capsules > Tablets (general trend, but highly drug-dependent). Parenteral (IV) bioavailability is 100%.
• C. Manufacturing Process: Particle size reduction, granulating method, compression force in tablets.

5.2.4. First-Pass Metabolism (Presystemic Elimination)

• For orally administered drugs, the drug is absorbed from the GI tract into the portal vein and passes through the liver before entering the general circulation. The liver can metabolize a significant fraction of the drug, reducing its systemic bioavailability.
• Drugs with high hepatic extraction ratios (e.g., propranolol, lidocaine, verapamil, morphine) exhibit significant first-pass metabolism, requiring larger oral doses compared to IV doses.
• Other sites of first-pass metabolism include the gut lumen (e.g., peptidases), gut wall (e.g., CYP450 enzymes), and lungs (for inhaled drugs).

5.3. Methods to Determine Bioavailability

Bioavailability is determined by measuring drug concentration in systemic circulation over time following administration, typically using plasma concentration-time curves.

5.3.1. In Vivo Methods (Plasma Concentration-Time Data)

• A. Plasma Concentration-Time Profile: Blood samples are collected at various time points after drug administration, and drug concentrations are measured.
• B. Pharmacokinetic Parameters Derived:
  • Area Under the Curve (AUC): Represents the total systemic exposure to the drug. Directly proportional to the dose absorbed.
  • Cmax (Peak Plasma Concentration): Maximum drug concentration attained in plasma. Reflects the extent of absorption.
  • Tmax (Time to Reach Peak Concentration): Time required to reach Cmax. Reflects the rate of absorption.

5.3.2. In Vitro Methods (Dissolution Testing)

While not a direct measure of bioavailability, in vitro dissolution testing is crucial for quality control and predicting in vivo performance, especially for immediate-release solid dosage forms. It measures the rate and extent to which a drug dissolves in a specific medium under controlled conditions. An in vitro-in vivo correlation (IVIVC) establishes a relationship between a product's in vitro property (e.g., dissolution rate) and an in vivo pharmacokinetic parameter (e.g., plasma concentration, AUC).

6. Bioequivalence

In simpler terms, two drug products (e.g., a brand-name drug and its generic counterpart) are considered bioequivalent if they show comparable bioavailability (i.e., similar Cmax, Tmax, and AUC). This ensures that generic drugs perform in the body in the same way as their reference listed drug (RLD) counterparts.

6.1. Criteria for Bioequivalence

Regulatory agencies (e.g., FDA, EMA) typically require that the 90% confidence interval for the ratio of the mean AUC and Cmax (Test/Reference) should fall within the range of 80% to 125% for most drugs. The Tmax is often evaluated for significant differences in the rate of absorption, but usually not subjected to the 80-125% interval for the ratio.

6.2. Importance of Bioequivalence

• Generic Drug Approval: Essential for the approval and marketing of generic drug products, ensuring they are therapeutically interchangeable with the innovator product without compromising efficacy or safety.
• Cost-Effectiveness: Facilitates access to more affordable medications by allowing generic competition.
• Public Health: Guarantees that patients receive consistent therapeutic effects regardless of whether they take a brand-name or generic product.

7. Strategies to Enhance Bioavailability

For drugs with poor bioavailability, various formulation and chemical modification strategies are employed.

• A. Particle Size Reduction: Micronization, nanomilling (nanocrystals) increase surface area, enhancing dissolution rate of poorly soluble drugs (e.g., griseofulvin, fenofibrate).
• B. Salt Formation: Converting a weak acid or base into its salt form can significantly increase its solubility and dissolution rate (e.g., diclofenac sodium vs. diclofenac free acid).
• C. Prodrug Approach: Chemically modifying the drug to improve its physicochemical properties (e.g., increased solubility, permeability) or to target specific enzymes for activation (e.g., levodopa converted to dopamine in brain, fosphenytoin is a water-soluble prodrug of phenytoin).
• D. Solid Dispersions: Dispersing a poorly soluble drug in an inert, water-soluble carrier (e.g., PEG, PVP) at the molecular level. This improves wettability and dissolution (e.g., itraconazole).
• E. Complexation with Cyclodextrins: Cyclodextrins are cyclic oligosaccharides that can encapsulate drug molecules, forming inclusion complexes that enhance solubility and dissolution (e.g., itraconazole oral solution with hydroxypropyl-β-cyclodextrin).
• F. Lipid-Based Formulations (LBFs): Incorporating drugs into oils, self-emulsifying drug delivery systems (SMEDDS), or liposomes. These enhance solubility and protect drugs from degradation, often improving absorption, especially for lipophilic drugs (e.g., ritonavir).
• G. pH Adjustment and Buffering: Optimizing the pH of the GI environment or the formulation itself to maintain the drug in its most soluble and permeable form.
• H. Permeation Enhancers: Substances that temporarily increase the permeability of biological membranes (e.g., EDTA, bile salts for oral; terpenes, fatty acids for transdermal).
• I. Nanoparticles/Nanosuspensions: Ultrafine particles of drug for improved solubility and cellular uptake.
• J. Effervescent Formulations: CO2 generation can increase drug solubility and promote drug absorption by increasing gastric pH and volume.

8. Clinical Relevance

The principles of dosage forms and bioavailability are not mere academic exercises; they are fundamental to effective clinical practice.

• A. Patient Outcomes: Ensuring optimal bioavailability is directly linked to achieving therapeutic drug concentrations, leading to desired clinical effects and avoiding sub-therapeutic or toxic levels.
• B. Drug Selection: Clinicians consider dosage form characteristics when prescribing, especially for patients with swallowing difficulties (e.g., liquids for pediatric/geriatric patients).
• C. Administration Guidelines: The specific instructions for administering a drug (e.g., 'take with food,' 'take on an empty stomach,' 'do not crush or chew') are often dictated by bioavailability considerations and dosage form design. Crushing an extended-release tablet can lead to dose dumping and toxicity.
• D. Therapeutic Drug Monitoring (TDM): For drugs with a narrow therapeutic index (e.g., digoxin, phenytoin), understanding individual bioavailability variations is crucial for dose adjustments based on TDM.
• E. Drug Interactions: Food-drug or drug-drug interactions can significantly alter bioavailability, requiring dose adjustments or careful timing of administration